Not sure they will get another opportunity like this, but you never know with IMGN. Let's watch to see if they give execs some more cheap shares after the decline, that would really tick off the shareholders.
John Lambert's presentation on 289 was impressive. 289 has the potential to be huge if IMGN can ever develop something successfully. Hopefully, they will partner and not with LLY since this would knock out Erbitux. The naked molecule alone is better than Erbitux and with the war head added, it's far more effective (in their models), but they have to get it to market on a timely basis. Let's have some bids to keep the price competitive, then hire Roche again to expedite development speed. The bidding should open at $100MM up front, large milestones and 25% of the gross revenue, with no hurdles, or restrictions. Partner does everything after phase I dose finding trials. This could win the new FDA special designation.
529 and 853 have some competition. B-cell market is huge, but there are some effective therapies. 853 may be more safe and effective than Rituxan and others...like T-DM1 vs Herceptin. Endocyte has a folate drug that is more advanced, so we will see which is more safe and effective. It's time for shorts to cover and move on to greener pastures.